Sign in

CIK 0001626971 · Non-accelerated filer<br>Smaller reporting company

Corvus Pharmaceuticals, Inc.

Sign in to watch
Ticker
CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
464670809
Phone
(650) 900-4520
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$50,475
in 1 filing
Open-market sales, last 90 days
$0
in 0 filings

Net +$50,475. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Arcara Jeffrey +$50K Chief Business Officer 1 filing
Date Insider Transaction Shares Price Value Owned after
2016-03-29 Gould Terry P Director Conversion · Series B Convertible Preferred Stock −71,863 0
2016-03-29 Gould Terry P Director Conversion · Series A Convertible Preferred Stock −583,510 0
2016-03-29 Gould Terry P Director Conversion · Series B Convertible Preferred Stock −97,746 0
2016-03-22 Jones William Benton VP Pharmaceutical Development Grant or award · Stock Option (Right to Buy) +60,000 60,000
2016-03-22 Krognes Steve E. Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2016-03-22 MILLER RICHARD A MD President and CEO Grant or award · Stock Option (Right to Buy) +500,000 500,000
2016-03-22 Thompson Peter A. Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2016-03-22 LEA LEIV Chief Financial Officer Grant or award · Stock Option (Right to Buy) +60,000 60,000
2016-03-22 Verner Erik J. V.P., Chemistry Research Grant or award · Stock Option (Right to Buy) +60,000 60,000
2016-03-22 Gould Terry P Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2016-03-22 ADAMS STREET PARTNERS LLC 10% owner Grant or award · Stock Option (Right to Buy) +30,000 30,000

Page 19 of 19 · 371 trades